Skip to main content

Year: 2022

Puma Exploration Launches Expanded Metallurgical Study Following 99.7% Gold Recovery From Preliminary Tests

Figure 1: Location of the eight HQ holes drilled at the LGZ Location of the eight HQ holes drilled at the LGZFigure 3: The Williams Brook Gold Project The Williams Brook Gold ProjectFigure 2: Location of the 12 significant quartz veins sampled at the LGZ Location of the 12 significant quartz veins sampled at the LGZPicture 1: Typical quartz vein sampled at the LGZ Typical quartz vein sampled at the LGZRIMOUSKI, Quebec, Nov. 15, 2022 (GLOBE NEWSWIRE) — Puma Exploration Inc. (TSXV: PUMA, OTCQB: PUMXF) (the “Company” or “Puma”) is pleased to announce that it has launched a significant metallurgical study at its Williams Brook Gold Project following exceptional results from a preliminary metallurgical test conducted this past summer. Mineral processing recovered up to 99.7% gold from samples drilled...

Continue reading

TRX Gold Declares Commercial Production of 1,000+ TPD Processing Plant

TORONTO, Nov. 15, 2022 (GLOBE NEWSWIRE) — TRX Gold Corporation (TSX:TNX) (NYSE American:TRX) (the “Company” or “TRX Gold”) is pleased to report the declaration of commercial production of the 1,000+ tonne per day (“tpd”) processing plant at the Buckreef Gold Mine (“Buckreef Gold”), effective November 2022. The declaration of commercial production for the 1,000+ tpd processing plant at Buckreef Gold in Tanzania is made after successful construction, commissioning and ramp-up of processing to a steady state throughput of 1,000+ tpd. The processing plant has now been running consistently at or above nameplate capacity since October 2022 with gold recoveries exceeding 90%. All major construction activities have been completed and Buckreef Gold has demonstrated its ability to sustain ongoing production levels. The mine will continue...

Continue reading

Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress

AFM13: Secured access to commercially viable natural killer (NK) cell product to accelerate clinical development of AFM13 and address the high unmet need of CD30-positive lymphoma patients through a collaboration with Artiva Biotherapeutics; an Investigational New Drug (IND) application filing is expected in H1 2023AFM13 combination with NK cells: As of July 31, 2022 in 24 patients with CD30-positive lymphoma treated at the highest dose level of the combination treatment of AFM13 with allogeneic cord-blood derived NK cells continues to achieve a 100% overall response rate (ORR) and an improved 70.8% complete response rate (CR)AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in mid-December 2022AFM24: Updated data from AFM24-101 and AFM24-102 presented at the Society for Immunotherapy...

Continue reading

Power Tools Market Size Worth USD 35.13 Billion, Globally, by 2029 at 4% CAGR

According to Fortune Business Insights, the global Power Tools market size is projected to grow from USD 25.87 billion in 2021 to USD 35.13 billion in 2029, at CAGR of 4% during forecast period; Pune, India, Nov. 15, 2022 (GLOBE NEWSWIRE) — The global Power Tools Market was USD 25.87 billion in 2021. The global market size is expected to be USD 26.61 billion in 2022 and is projected to reach USD 35.13 billion by 2029, exhibiting a CAGR of 4% during the forecast period from 2022-2029. This information is provided by Fortune Business Insights, in its report, titled, “Power Tools Market, 2022-2029.” According to our analysts, the construction and automotive industries will exhibit profound demand for power tools. Stakeholders will continue to inject funds into advanced tools to boost comfort amidst the soaring popularity of cordless...

Continue reading

With 10.4 % CAGR, Mucopolysaccharidosis Treatment Market Size worth USD 4.37 Billion in 2026

According to Fortune Business Insights, The Mucopolysaccharidosis Treatment Market size is anticipated to reach USD 4.37 Billion by 2026, the market size was USD 1.98 billion in 2018 and is anticipated to rise at a CAGR of 10.4% Pune, India, Nov. 15, 2022 (GLOBE NEWSWIRE) — The global mucopolysaccharidosis treatment market size is predicted to reach USD 4.37 billion by 2026, exhibiting a CAGR of 10.4% during the forecast period. The growing cases of rare diseases can be critical factor in fuelling the demand for mucopolysaccharidosis treatment, which in turn, will aid the expansion of the market. Moreover, the increasing R&D investments by key players for new therapeutics will have a positive impact on the mucopolysaccharidosis treatment market growth. In addition, the growing awareness regarding the novel therapies to treat...

Continue reading

US Pharmacy Market Size [2021-2028] Exhibits 6.3% CAGR to Reach USD 861.67 Billion in 2028

According to Fortune Business Insights, the global US Pharmacy Market size is projected to reach USD 861.67 Billion by 2028, at CAGR of 6.3% during forecast period; Growing Occurrence of Prolonged Disease and High Geriatric Population to Spur Demand Pune, India, Nov. 15, 2022 (GLOBE NEWSWIRE) — The US pharmacy market size was USD 534.21 billion in 2020. The market is projected to grow from USD 560.00 billion in 2021 to USD 861.67 billion by 2028 at a CAGR of 6.3% in the 2021-2028 period. This information is published by Fortune Business Insights™, in its report, titled, “US Pharmacy Market, 2021-2028.” According to our expert researchers, surging occurrence of aliments in the US, growing geriatric population, and rising healthcare spending are few of the prime aspects fueling the growth of the pharmaceuticals market in the...

Continue reading

SalMar – update of issuer rating from Nordic Credit Rating

Nordic Credit Rating has today 15th of November 2022 updated its issuer rating of SalMar ASA and assigned the company BBB+ with stable outlook. See link below for more information.https://nordiccreditrating.com/issuer/salmar-asa             For more information, please contact.Håkon Husby, IR-ansvarligTel: +47 936 30 449Email: hakon.husby@salmar.no

Continue reading

SunHydrogen Announces $10M Strategic Investment in Norway-Based TECO 2030 ASA

SANTA BARBARA, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) — SunHydrogen, Inc. (OTC: HYSR), the developer of a breakthrough technology to produce renewable hydrogen using sunlight and water, today announced that it has invested $10M in TECO 2030 ASA (Oslo Stock Exchange: TECO, OTCQX: TECFF). A Norway-based company, TECO 2030 is the developer of zero-emission technology for the maritime and heavy industry sectors. TECO 2030 is currently accelerating the transition to renewable fuels by developing and building Europe’s first gigafactory of hydrogen PEM fuel cell stacks for medium to heavy-duty trucks and PEM fuel cell modules for maritime applications. Most recently, TECO 2030, Shell, and additional partners received €5 million in funding from Horizon Europe to realize the HyEkoTank, a hydrogen powered tanker that will look to lead the maritime...

Continue reading

With 6.0% CAGR, Veterinary Vaccines Market Size Hit USD 16.13 Billion in 2028

According to Fortune Business Insights, The global veterinary vaccines market size was USD 10.24 billion in 2020. The market is set to grow from USD 10.73 billion in 2021 and reach USD 16.13 billion in 2028 at a CAGR of 6.0% in the 2021-2028 period. Pune, India, Nov. 15, 2022 (GLOBE NEWSWIRE) — The global veterinary vaccines market size was USD 10.24 billion in 2020. The market is set to grow from USD 10.73 billion in 2021 and reach USD 16.13 billion in 2028 at a CAGR of 6.0% in the 2021-2028 period. This information is provided by Fortune Business Insights™ in its report titled, “Veterinary Vaccines Market, 2021-2028.” As per our researchers, the substantial growth of the market is mainly owing to increased adoption of pet animals worldwide, greater spending on pet maintenance, and escalating implementation of proficient...

Continue reading

China Index Holdings Announces Third Quarter 2022 Unaudited Financial Results

BEIJING, Nov. 15, 2022 (GLOBE NEWSWIRE) — China Index Holdings Limited (NASDAQ: CIH), (“CIH” or the “Company”), a leading real estate information and analytics service platform provider in China, today announced its unaudited financial results for the third quarter ended September 30, 2022. Third Quarter 2022 HighlightsTotal revenues were RMB97.7 million, a decrease of 39.3% from RMB160.8 million in the corresponding period of 2021. Operating income was RMB30.9 million, a decrease of 60.4% from RMB78.0 million in the corresponding period of 2021. Net income was RMB27.6 million, a decrease of 62.1% from RMB72.8 million in the corresponding period of 2021.Third Quarter 2022 Financial Results Revenues CIH reported total revenues of RMB97.7 million in the third quarter of 2022, a decrease of 39.3% from RMB160.8 million in the corresponding...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.